When a son is diagnosed with Duchenne muscular dystrophy, the genetic counseling that follows almost always turns to his mother. She may learn that she carries the mutation, and the conversation usually reassures her in the same breath: carriers don't get muscular dystrophy. That much is accurate, and her muscles will work normally her whole life. What often goes unsaid is that her heart may not.

Between 30 and 50 percent of women who carry a DMD mutation develop some degree of cardiomyopathy, a weakening of the heart muscle, often long before they'd think to look for it. The muscle disease skips them. The cardiac risk does not. Understanding why comes down to a single gene and the way the body decides which copy of it to use.

Why a Carrier's Heart Is at Risk

The dystrophin gene sits on the X chromosome. Boys have one X, so a single broken copy leaves them with no working dystrophin, and Duchenne follows. Women have two X chromosomes, and a carrier has one healthy copy and one mutated copy. On paper, the healthy copy should cover for the broken one everywhere in the body.

The complication is a process called X-inactivation. Early in development, every cell in a female body permanently switches off one of its two X chromosomes, chosen at random. Some cells silence the mutated copy and run on the healthy one. Others silence the healthy copy and are left producing faulty dystrophin, the same as a boy with the disease. The body becomes a mosaic.

In skeletal muscle, the cells that still make dystrophin can compensate for the ones that don't, which is why carriers keep their strength. Cardiac muscle is less forgiving. Heart cells don't regenerate the way skeletal muscle can, and there's no reserve pool to cover for the ones running short. When a meaningful fraction of cardiac cells lack dystrophin, the heart muscle slowly loses its ability to contract efficiently. That's the origin of a carrier's cardiomyopathy, and it explains why the risk shows up in the heart while sparing the arms and legs.

What the Symptoms Look Like, and When They Appear

Carrier cardiomyopathy tends to arrive quietly and later than the disease does in boys. Many carriers show the first measurable changes in their 30s and 40s, though the range is wide. The early stage is usually silent, detectable on imaging before a woman feels anything at all.

When symptoms do surface, they read like ordinary fatigue, which is part of what makes them easy to miss:

• Shortness of breath during activity that used to feel easy
• Swelling in the ankles, feet, or legs
• A racing, fluttering, or irregular heartbeat
• Unusual tiredness or reduced stamina
• Lightheadedness, particularly on exertion

A mother raising a child with significant medical needs has a ready explanation for every one of these, and it's rarely her own heart. The symptoms are nonspecific, the cause is invisible without imaging, and the woman most at risk is usually the one paying attention to everyone but herself.

The Screening Every Carrier Should Have

Cardiac screening for carriers is straightforward, and it's where knowing the risk turns into something you can act on. The American Academy of Pediatrics and cardiology specialty groups recommend that any woman confirmed or suspected to carry a DMD mutation establish care with a cardiologist, ideally one familiar with neuromuscular cardiac disease.

A reasonable baseline looks like this:

• An echocardiogram or cardiac MRI in late adolescence or early adulthood to establish a starting point
• Repeat imaging every three to five years if the baseline is normal
• More frequent monitoring if any imaging is abnormal, if symptoms appear, or if there's a family history of carrier cardiomyopathy

Cardiac MRI is worth asking about by name. It can detect fibrosis, the scarring that precedes a drop in pumping function, earlier than a standard echocardiogram can. For a carrier with a normal echo who wants a closer look, MRI is often the more sensitive tool.

The reassuring part is that detection leads somewhere. The same medications used to protect the hearts of boys with DMD, ACE inhibitors and beta-blockers among them, work for symptomatic carriers. Started early, they can slow the decline in heart function well before a woman would notice any limitation in daily life. This is the argument for the baseline scan even when you feel completely well, since the window where treatment does the most good opens before symptoms do. It mirrors the logic behind the cardiac monitoring schedule recommended for affected boys, applied to the woman who shares the mutation.

The Conversation Beyond Yourself

Carrier status runs along the maternal line, which means the risk rarely stops with one woman. If a mother carries a DMD mutation, her sisters, her mother, and her daughters may carry it too, each with the same cardiac odds and often the same blind spot. Many have never been told that a heart evaluation applies to them.

Genetic counseling can clarify who in a family should be tested and who would benefit from cardiac screening even without genetic confirmation. For families already navigating a child's diagnosis, adding one more set of appointments can feel like too much. The trade is favorable: a baseline echo takes an afternoon, repeats every few years, and catches a treatable condition at the stage where treatment matters most. For a woman who spends her days managing someone else's care, that afternoon is one of the few that protects her own.